Inner Salt (e.g., Betaine, Etc.) Patents (Class 514/77)
  • Patent number: 10806741
    Abstract: Methods of treating infections caused by free-living amoeba are disclosed. The methods generally include systemic administration of an effective amount of miltefosine, such as an oral or intravenous formulation, and optionally local administration of an effective amount of miltefosine, such as a topical formulation of miltefosine. The methods may further include administration of one or more secondary agents. Exemplary secondary agents include steroids, polyhexamethylene biguanide (PHMB), chlorhexidine, propamidine isethionate, dibromopropamidine isethionate, neomycin, paromomycin, polymyxin B, clotrimazole, ketoconazole, miconazole, and itraconazole. The methods may be used to treat patients with infections caused by a free-living amoeba such as Naegleria fowleri, Balamuthia mandrillaris, Sappinia diploidea, and Acanthamoeba species.
    Type: Grant
    Filed: July 18, 2019
    Date of Patent: October 20, 2020
    Assignee: Profounda, Inc.
    Inventor: Todd Ewen MacLaughlan
  • Patent number: 10191032
    Abstract: This invention relates to a method for detecting the presence of or likelihood of a patient of developing occult pancreatic beta cell dysfunction, and a method for detecting the presence of or likelihood of a patient of developing clinically significant post-prandial hyperglycemia. The methods involve (a) measuring a level of alpha-hydroxybutyrate (AHB) in a single fasting baseline biological sample of the patient; (b) comparing the level of AHB in the single fasting baseline biological sample to a reference AHB level; and (c) determining the presence of or likelihood of developing the disorder in the patient based on the comparison in step (b). An increased AHB level at fasting baseline indicates that a normoglycemic, normo-insulinemic and/or non-dyslipidemic patient has developed or has an increased likelihood of developing occult pancreatic beta cell dysfunction.
    Type: Grant
    Filed: January 13, 2014
    Date of Patent: January 29, 2019
    Assignee: True Health IP LLC
    Inventors: Steve Varvel, Rebecca E. Caffrey, James V. Pottala
  • Patent number: 10065978
    Abstract: Compounds are generally provided, along with pharmaceutical compositions including such compounds. Methods are also generally provided for inhibiting ribose 5-phosphate isomerase in a human, such as via administering to the human the pharmaceutical composition that includes such a compound. Methods are also generally provided for treating a mammal that is infected by a parasitic organism, such as via administering to the mammal the pharmaceutical composition that includes such a compound. Methods are also generally provided for forming a pharmaceutical composition.
    Type: Grant
    Filed: November 23, 2016
    Date of Patent: September 4, 2018
    Assignee: University of South Carolina
    Inventor: Edward L. D'Antonio
  • Patent number: 10054589
    Abstract: The present invention is directed toward novel methods to identify as well as to treat a subject having an inflammatory disease resistant to corticosteroids.
    Type: Grant
    Filed: February 12, 2014
    Date of Patent: August 21, 2018
    Assignee: National Jewish Health
    Inventors: Donald Y. M. Leung, Elena Goleva, Lingbo Li
  • Patent number: 9980907
    Abstract: The invention relates to a thermolabile liposome with a controlled release temperature for the liposome content, in particular a liposome which is stable at 37° C. in serum and with a controlled release temperature of between 40 and 80° C.
    Type: Grant
    Filed: June 17, 2010
    Date of Patent: May 29, 2018
    Assignee: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.
    Inventors: Hansj{hacek over (o)}rg Eibl, Lars H. Lindner
  • Patent number: 9915645
    Abstract: This invention relates to a method for detecting the presence of or likelihood of a patient of developing occult pancreatic beta cell dysfunction, and a method for detecting the presence of or likelihood of a patient of developing clinically significant post-prandial hyperglycemia. The methods involve (a) measuring a level of alpha-hydroxybutyrate (AHB) in a single fasting baseline biological sample of the patient; (b) comparing the level of AHB in the single fasting baseline biological sample to a reference AHB level; and (c) determining the presence of or likelihood of developing the disorder in the patient based on the comparison in step (b). An increased AHB level at fasting baseline indicates that a normoglycemic, normo-insulinemic and/or non-dyslipidemic patient has developed or has an increased likelihood of developing occult pancreatic beta cell dysfunction.
    Type: Grant
    Filed: January 13, 2014
    Date of Patent: March 13, 2018
    Assignee: True Health IP LLC
    Inventors: Steve Varvel, Rebecca E. Caffrey, James V. Pottala
  • Patent number: 9670174
    Abstract: Linear mono- and dialkyl ethers of furan-2,5-dimethanol (FDM) and/or 2,5-bis(hydroxymethyl)tetrahydrofuran (bH-MTHF), methods for their preparation, and derivative chemical compounds thereof are described. In general, the synthesis process entails a reaction of FDM or bHMTHFs in a polar aprotic organic solvent having a permittivity ( )>8, at a temperature ranging from about ?25 C to about 100 C, with either a) an unhindered Brnsted base with a pKa?15 or b) a hindered Brnsted base having minimum pKa of about 16, and a nucleophile.
    Type: Grant
    Filed: December 12, 2014
    Date of Patent: June 6, 2017
    Assignee: Archer Daniels Midland Company
    Inventor: Kenneth Stensrud
  • Patent number: 9655911
    Abstract: The combined use of 1,2-dilinoleoyl-sn-glycero-3-phosphocholine and 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine affords a superior anti-depressive action, an improving effect on the cognitive function associated with depression, an improving effect on the stress-induced suppression of Akt activation, and a suppressive action on the stress-induced GSK-3? activation. Therefore, the present invention can provide an antidepressant combination drug, an agent for improving cognitive function associated with depression, an agent for improving stress-induced suppression of Akt activation and an agent for suppressing stress-induced GSK-3? activation.
    Type: Grant
    Filed: October 14, 2014
    Date of Patent: May 23, 2017
    Assignee: Nishizaki Bioinformation Research Institute
    Inventor: Tomoyuki Nishizaki
  • Patent number: 9434753
    Abstract: The invention discloses creatine derivatives that are represented by Formula (I), Formula (II), and Formula (III); wherein Z is a functional group; Y is a mitochondrial targeting agent, a cationic ammonium group, or a polypeptide containing at least one positively charged amino acid residue; each R1 is independently hydrogen, alkyl, or a phosphate group; R2 a linker; R3 is a spacer group; R4 is hydrogen, alkyl, aryl, or heterocyclic; or R4 and R1, or R4 and R3, together with the nitrogen atoms to which they are attached form a heterocyclic ring, and W is hydrogen or alkyl.
    Type: Grant
    Filed: September 18, 2012
    Date of Patent: September 6, 2016
    Assignee: Gencia Corporation
    Inventors: Shaharyar M. Khan, Robert Gadwood, Arthur Glenn Romero
  • Patent number: 9358244
    Abstract: The present invention relates to solid dosage forms of oleyl phosphocholine (C18:1-PC), or OlPC, for oral administration. Further, the present invention relates to methods for the preparation of the present solid dosage forms and the use thereof as a medicament and especially a medicament for treatment of parasitic diseases, such as leishmaniasis, chagas and malaria, and cancer both in humans and animals. Specifically, the present invention relates to a solid dosage form comprising: 6 to 25 weight % of the solid dosage form oleyl phosphocholine; 20 to 35 weight % of the solid dosage form lactose; 35 to 50 weight % of the solid dosage form cellulose; 5 to 20 weight % of the solid dosage form croscarmellose; 1 to 10 weight % of the solid dosage form hydroxypropylmethyl cellulose; and 0.05 to 1 weight % of the solid dosage form of a lubricant.
    Type: Grant
    Filed: November 21, 2011
    Date of Patent: June 7, 2016
    Assignee: Oblita Therapeutics BVBA
    Inventors: Frans Herwig Jansen, Bruno Jansen
  • Patent number: 9326989
    Abstract: The invention relates to the use of oleyl phosphocholine and oleyl-phospho-(N.N.-dimethyl-N-ethyl)-ethyl-ammonium for the long-term and continuous treatment of serious illnesses, such as cancer, leishmaniasis, ehrlichiosis, multiple sclerosis and psoriasis, in addition to other indications mentioned in the application.
    Type: Grant
    Filed: March 26, 2008
    Date of Patent: May 3, 2016
    Assignee: Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V.
    Inventor: Hansjörg Eibl
  • Patent number: 9254298
    Abstract: Disclosed herein are formulations and methods of manufacture of compounds of formula (E): wherein X and Y independently represent leaving groups; and A+ is an ammonium cation.
    Type: Grant
    Filed: July 23, 2015
    Date of Patent: February 9, 2016
    Assignee: ZIOPHARM Oncology, Inc.
    Inventors: Frank W. Waligora, John C. Amedio, Jr.
  • Patent number: 9181116
    Abstract: The present invention relates to an organophosphonium derivative of the mean general formula (1), where n is a number comprised between 4 and 20, preferably between 5 and 10, m is a number between 0 and 10, preferably between 0 and 1, and Y is an anion. The invention also relates to a method for preparing same, and to a method for controlling the growth of bacterial biomass in an aqueous system, including adding to said aqueous system or contacting said aqueous system with an efficient amount of an uncoupling agent selected from an organophosphonium derivative as defined above.
    Type: Grant
    Filed: September 8, 2010
    Date of Patent: November 10, 2015
    Assignee: RHODIA OPERATIONS
    Inventors: Philippe Marchal, Vincent Schanen, Stephane Carret-Troncy, Mickael Berard, Luc Louvel, Agnes Pilas-Begue
  • Publication number: 20150132280
    Abstract: A human dietary supplement comprises theacrine and optionally other compounds that modulate the effects of theacrine. Uses for the theacrine-containing supplement include improvement of at least one of mood, energy, focus, concentration or sexual desire or a reduction of at least one of anxiety or fatigue.
    Type: Application
    Filed: November 12, 2014
    Publication date: May 14, 2015
    Applicant: ORTHO-NUTRA, LLC
    Inventors: Hector L Lopez, Shawn Wells, Tim N. Ziegenfuss
  • Patent number: 9012396
    Abstract: In one embodiment, the invention provides a method of suppressing, inhibiting, preventing, or treating conjunctivitis in a subject, comprising the step of administering an effective amount of a lipid or phospholipid moiety bound via an ester or amide bond to a physiologically acceptable monomer, dimer, oligomer, or polymer, and/or a pharmaceutically acceptable salt or a pharmaceutical product thereof to a subject with conjunctivitis.
    Type: Grant
    Filed: January 9, 2013
    Date of Patent: April 21, 2015
    Assignee: Yissum Research Development Company of The Hebrew University of Jerusalem
    Inventor: Saul Yedgar
  • Publication number: 20150071897
    Abstract: The present invention relates to a method of treatment and/or ameliorating the symptoms of Huntington's disease comprising the step of administering an effective amount of adenosine triphosphate, co-carboxylase, nicotinamide, and cyanocobalamin in a physiologically acceptable carrier to an individual in need thereof. Preferably, the administration is via intramuscular injection.
    Type: Application
    Filed: November 12, 2014
    Publication date: March 12, 2015
    Inventor: Ragab El-Rashidy
  • Publication number: 20150065561
    Abstract: The present invention is based, in part, on our studies of molecular pathways that include the deubiquitinase CYLD. Accordingly, the present invention features, inter alia, nucleic acid constructs that express CYLD or a biologically active variant thereof (e.g., a variant including the catalytic domain), nucleic acids that inhibit the expression of a negative regulator of CYLD (e.g., PDE4B or LNK2), nucleic acids that modulate the expression of downstream CYLD targets (e.g., Akt, by inhibiting or promoting the expression of the downstream target), compositions including one or more of these types of constructs (e.g., pharmaceutical compositions), kits including one or more of the compositions described herein and instructions for use, screening methods to identify therapeutic agents {e.g., anti-inflammatory agents) that upregulate CYLD, downregulate a negative regulatory of CYLD, or modulate (e.g., inhibit) a downstream CYLD target (e.g.
    Type: Application
    Filed: April 9, 2013
    Publication date: March 5, 2015
    Applicant: Georgia State University Research Foundation, Inc.
    Inventor: Jian-Dong Li
  • Publication number: 20150065461
    Abstract: The present invention relates to vesicular formulations for use in the treatment of pain and/or reduced mobility associated with a loss of lubrication and/or structural integrity and/or swelling of a collagen structure. It also relates to a method of treating pain such as joint pain or tendonitis comprising topically administering a vesicular formulation according to the invention.
    Type: Application
    Filed: April 12, 2013
    Publication date: March 5, 2015
    Inventors: Richard Wolf Garraway, Michael Earl, Saruhan Yurdakul, Nicholas Baverstock
  • Publication number: 20150065460
    Abstract: Biomarkers relating to pancreatic Beta-cell function, pancreatic Beta-cell glucose sensitivity, insulin resistance, and/or pancreatic Beta-cell-related disorders are provided. Methods based on the same biomarkers are also provided.
    Type: Application
    Filed: September 11, 2012
    Publication date: March 5, 2015
    Inventors: Walter Gall, Kay A. Lawton
  • Publication number: 20150065431
    Abstract: The present invention provides methods of reducing cutaneous scar formation by treating a cutaneous wound with a composition comprising a therapeutic agent that is a sodium channel blocker and/or an inhibitor of the Nax/SCN7A pathway. The present invention also provides wound cover components impregnated with such compositions, kits composed of such compositions with a wound dressing or sterile wipe, and mixtures of such compositions with a topical component (e.g., cream, ointment, or gel) suitable for application to a cutaneous wound. The present invention also provides compositions, kits, devices, and methods for treating skin conditions (e.g., dermatitis, psoriasis, or other skin conditions) with such compositions and devices. Examples of such therapeutic agents include, but are not limited to, an inhibitor of a gene or protein selected from: ENac, COX-2, PGE2, PI3K, PKB, Nax Prss8, IL-1?, IL-8, SAPK, Erk gene, p38 gene, PAR2, S100A8, S100A9, S100A12.
    Type: Application
    Filed: August 27, 2014
    Publication date: March 5, 2015
    Inventors: Wei Xu, Seok Jong Hong, Robert D. Galiano, Thomas A. Mustoe
  • Publication number: 20150057249
    Abstract: The present invention relates to vesicular formulations for the treatment of rosacea. It also relates to a method of treating rosacea comprising administering a vesicular formulation according to the invention.
    Type: Application
    Filed: March 28, 2013
    Publication date: February 26, 2015
    Inventors: John Mayo, William Henry
  • Publication number: 20150005258
    Abstract: The invention discloses creatine derivatives that are represented by Formula (I), Formula (II), and Formula (III); wherein Z is a functional group; Y is a mitochondrial targeting agent, a cationic ammonium group, or a polypeptide containing at least one positively charged amino acid residue; each R1 is independently hydrogen, alkyl, or a phosphate group; R2 a linker; R3 is a spacer group; R4 is hydrogen, alkyl, aryl, or heterocyclic; or R4 and R1, or R4 and R3, together with the nitrogen atoms to which they are attached form a heterocyclic ring, and W is hydrogen or alkyl.
    Type: Application
    Filed: September 18, 2012
    Publication date: January 1, 2015
    Applicant: Genci Corporation
    Inventors: Shaharyar M. Khan, Robert Gadwood, Arthur Glenn Romero
  • Publication number: 20140356455
    Abstract: Methods of generating cell lines with a sequence variation or copy number variation of a gene of interest, methods of use thereof, and cell lines with a sequence variation or copy number variation of a gene of interest are provided.
    Type: Application
    Filed: December 6, 2013
    Publication date: December 4, 2014
    Applicants: The Board of Trustees of the Leland Stanford Junior University, Parkinson's Institute
    Inventors: Renee Ann Reijo Pera, J. William Langston, Birgitt Schule, Theodore D. Palmer, Blake Byers, Ha Nam Nguyen, James Anthony Byrne, Branden John Cord
  • Publication number: 20140349967
    Abstract: The present invention relates to novel crystalline forms of sodium salt of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide (e.g., NXL-104) thereof. The present invention relates to compositions comprising a crystalline form of sodium salt of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide (e.g., NXL-104) alone or in combination with an antibacterial agent (e.g., ceftaroline fosamil). Processes for the preparation of the crystalline forms and methods of treating bacterial infections by administering the crystalline forms alone or in combination with an antibacterial agent (e.g., ceftaroline fosamil) are also described.
    Type: Application
    Filed: August 7, 2014
    Publication date: November 27, 2014
    Inventors: Mahendra G. Dedhiya, Sisir Bhattacharya, Véronique Ducandas, Alexandre Giuliani, Valérie Ravaux, Alain Bonnet, Alain Priour, Peter Spargo
  • Publication number: 20140328909
    Abstract: A method of treating and alleviating joint pain includes administering a therapeutic amount of a composition comprising krill oil reacted with astaxanthin. A medicine delivery system for the method and composition includes an inner capsule containing carotenoids and an outer capsule in which the inner capsule is contained within the outer capsule and the outer capsule containing a therapeutically effective amount of krill oil. In one example, the carotenoids comprise at least S, S?-astaxanthin derived from Haematococcus pluvialis.
    Type: Application
    Filed: July 21, 2014
    Publication date: November 6, 2014
    Inventors: JOHN A. MINATELLI, W. STEPHEN Hill, RUDI E. MOERCK
  • Publication number: 20140308345
    Abstract: A method of enhancing cardiovascular health includes administering a therapeutic amount of a composition comprising krill oil reacted with astaxanthin. A medicine delivery system for the method and composition includes an inner capsule containing carotenoids and an outer capsule in which the inner capsule is contained within the outer capsule and the outer capsule containing a therapeutically effective amount of krill oil. In one example, the carotenoids comprise at least S, S?-astaxanthin derived from Haematococcus pluvialis.
    Type: Application
    Filed: June 17, 2014
    Publication date: October 16, 2014
    Inventors: JOHN A. MINATELLI, W. STEPHEN HILL, RUDI E. MOERCK
  • Publication number: 20140274957
    Abstract: The present invention includes compositions and methods for treating certain conditions, the composition comprising a choline compound; a cholinesterase inhibitor; and Acetyl-L-Carnitine, wherein the composition is used to treat at least one of autonomic dysfunctions or vascular diseases.
    Type: Application
    Filed: March 13, 2014
    Publication date: September 18, 2014
    Inventor: Diana Driscoll
  • Publication number: 20140271923
    Abstract: Patients inflicted with various clustering chronic diseases require treatment with multiple drugs having distinct mechanisms of action. Accordingly, patients with multiple conditions suffer from cumulative side effects of multiple drugs as well as drug-drug interactions. Embodiments, agents, compounds or drugs of the present invention, such as sesquiterpenes, e.g., Zerumbone, replace an equal or larger number of approved drugs during patient treatment. Examples of disorders prevented or ameliorated by administration of the formulations of this invention include but are not limited to inflammatory diseases that may be, oncological, genetic, ischemic, infectious, neurological, hematological, ophthalmological, rheumatoid, orthopedic, neurological, hematological, kidney, vascular, dermatological, gynecological, or obstetric.
    Type: Application
    Filed: March 14, 2013
    Publication date: September 18, 2014
    Inventor: Christopher Brian Reid
  • Publication number: 20140274956
    Abstract: The disclosure relates to method of typing a sample from an individual as a sample from an individual with an increased life expectancy, an average life expectancy or a reduced life expectancy. The typing is based on a comparison of a level of lipid species in a sample of the individual to a level of lipid species in a reference. The disclosure further relates to a composition comprising lipid species for use in increasing life expectancy of an individual.
    Type: Application
    Filed: March 13, 2014
    Publication date: September 18, 2014
    Applicants: Universiteit Leiden, Academisch Ziekenhuis Leiden h.o.d.n. LUMC
    Inventors: Pieternella Slagboom, Thomas Hankemeier
  • Patent number: 8835455
    Abstract: The present invention relates to novel crystalline forms of sodium salt of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide (e.g., NXL-104) thereof. The present invention relates to compositions comprising a crystalline form of sodium salt of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide (e.g., NXL-104) alone or in combination with an antibacterial agent (e.g., ceftaroline fosamil). Processes for the preparation of the crystalline forms and methods of treating bacterial infections by administering the crystalline forms alone or in combination with an antibacterial agent (e.g., ceftaroline fosamil) are also described.
    Type: Grant
    Filed: May 24, 2013
    Date of Patent: September 16, 2014
    Inventors: Mahendra G. Dedhiya, Sisir Bhattacharya, Véronique Ducandas, Alexandre Giuliani, Valérie Ravaux, Alain Bonnet, Alain Priour, Peter Spargo
  • Patent number: 8828972
    Abstract: The invention relates to novel medicament formulations containing, as active ingredients, alkylphosphocholines and the like, alkyl-alkanediol-phosphocholines and the like, and (ether)lysolecithins and the like, in different forms of embodiment. The active ingredients are integral constituents of liposomes, also containing cholesterol and the like and a negative charge carrier. The medicament formulations are especially suitable for the treatment and/or prophylaxis of cancer, protozoan diseases such as leishmaniasis and amoebic diseases, acariasis and diseases caused by arthropods, and bacterial diseases, such as ehrlichiosis. Ocular diseases accompanied by uncontrolled cellular processes can also be advantageously influenced.
    Type: Grant
    Filed: October 19, 2005
    Date of Patent: September 9, 2014
    Assignee: Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V.
    Inventors: Hansjörg Eibl, Susanne Christine Wieland-Berghausen, Jean Steffan
  • Publication number: 20140227260
    Abstract: The present invention relates to new aminopyrimidine inhibitors of tyrosine kinase activity, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Application
    Filed: April 21, 2014
    Publication date: August 14, 2014
    Applicant: Auspex Pharmaceuticals, Inc.
    Inventor: Chengzhi Zhang
  • Publication number: 20140199265
    Abstract: The present disclosure relates to nutritional compositions comprising a neurologic component, wherein, the neurologic component may promote brain and nervous system development and further provide neurological protection and repair. The neurologic component may include phosphatidylethanolamine, sphingomyelin, cytidine diphosphate-choline, ceramide, uridine, at least one ganglioside, and mixtures thereof. The disclosure further relates to methods of promoting brain and nervous system health by providing said nutritional compositions to target subjects, which includes pediatric subjects.
    Type: Application
    Filed: January 11, 2013
    Publication date: July 17, 2014
    Applicant: Mead Johnson Nutrition Company
    Inventors: Chenzhong Kuang, Yan Xiao, Eduard Poels, Zeina Jouni, Dirk Hondmann
  • Publication number: 20140199367
    Abstract: The present invention relates to liquid application for skin rejuvenation created from specific amino acids, lipids, nucleic acids and vitamins. This collection of molecules delivers precisely the factors necessary to a specific site requiring healing; a direct intervention system to most expeditiously remodel skin with building blocks. This delivery is a transdermal topical delivery and healing is via specific molecules that engender a false autocoid reaction rapidly followed by an incremental healing-anti-inflammatory response augmented by very specific GRAS ingredients in the invention and also recruited from the body to this needy site. Energy is brought to site by transdermally delivered protons and enhanced by the local vascular flow initiated by transdermal molecules. This delivery system bypasses digestion and dilution. Key is a lipophilic carrier with nuclear and mitochondrial ligands that rapidly penetrate and permeate all membranes and truncates the inflammatory site quickly manifesting curation.
    Type: Application
    Filed: January 17, 2013
    Publication date: July 17, 2014
    Inventor: Donald P. Orofino
  • Patent number: 8765721
    Abstract: Provided is a composition comprising a phosphatidyl serine receptor ligand for use in immune therapy. The composition may include an antigen or allergen together with the phosphatidyl serine receptor ligand. The compositions may be used for any type of immune therapy, such as immune modulation to an environmental antigen or allergen, down regulation of immune hypersensitivity reactions, and stimulation of antigen or allergen specific IgA and/or IgG4.
    Type: Grant
    Filed: December 2, 2005
    Date of Patent: July 1, 2014
    Assignee: Vaccine Technology Limited
    Inventors: Antony Rodney Berry, Alan Worland Wheeler
  • Publication number: 20140135289
    Abstract: The present invention provides brain atrophy prevention agent comprising a phospholipid containing a highly unsaturated fatty acid as a constituent fatty acid, as an active ingredient.
    Type: Application
    Filed: April 5, 2013
    Publication date: May 15, 2014
    Applicant: NIPPON SUISAN KAISHA, LTD.
    Inventor: NIPPON SUISAN KAISHA, LTD.
  • Patent number: 8722648
    Abstract: The inventions relates to a liquid pharmaceutical form containing an active ingredient alkylphosphocholines and a co-solvent system. The co-solvent system is mixture from hexylene glycol, propylene glycol, diethylene glycol monoethyl ether and water. The pharmaceutical form having a pH value in the range of 4 to 6, which if it is necessary can be achieved by adding a pH adjuster. The composition has a good storage stability and it is suitable for local application on the different organs of the body. The inventions relates also to a method for producing the same pharmaceutical form.
    Type: Grant
    Filed: July 9, 2009
    Date of Patent: May 13, 2014
    Inventor: Paul Meng
  • Publication number: 20140100191
    Abstract: Disclosed herein are vesicular formulations that include one or more phospholipids and one or more surfactants and in certain embodiments the use of such formulations for the delivery of fatty acids for the treatment of disorders such as, fatty acid metabolic disorders, including essential fatty acid deficiency; pain or inflammation or osteoarthritis, more specifically for the treatment of deep tissue pain; asthma, bronchospasm, atherothrombatic cardiovascular disorders, avenous thrombatic disorders, inflammatory dermatoses disorders (e.g., atopic eczema, dishydrotic hand eczema, plaque type psoriasis, seborrheic eczema, and acne vulgaris), and dysmenorrhea.
    Type: Application
    Filed: October 16, 2013
    Publication date: April 10, 2014
    Inventors: Henk-Andre Kroon, William Henry
  • Publication number: 20140099354
    Abstract: The present invention relates to nitro-carboxylic acid (s)-containing phospholipids, to be used for coating of medical devices such as stents, catheter balloons, wound pads or surgical suture material and for bio-passivating compositions, such as rinses, waterproofing solutions, coating solutions, cryoprotection solutions, cold preservation media, lyoprotection solutions, contrast media solutions, preservation and reperfusion solutions containing these compounds as well as preparing solutions thereof and coating medical devices as well as their uses.
    Type: Application
    Filed: June 6, 2012
    Publication date: April 10, 2014
    Inventor: Ulrich Dietz
  • Publication number: 20140100192
    Abstract: The present invention provides choline alfoscerate-containing pharmaceutical preparations which have improved storage-stability and are easily taken. The present invention also provides a method for manufacturing pharmaceutical preparations comprising choline alfoscerate, which is easy and simple and is performed by normal manufacturing equipments.
    Type: Application
    Filed: December 12, 2013
    Publication date: April 10, 2014
    Applicant: CTC BIO, INC.
    Inventors: Bong-Sang LEE, Su-Jun PARK, Do-Woo KWON, Hong-Ryeol JEON
  • Publication number: 20140093554
    Abstract: The present invention relates to a nutritional composition for infants and/or toddlers comprising a lipid component which has a large lipid globule size. The composition can be used to increase bone mineral content and/or bone mass density.
    Type: Application
    Filed: June 10, 2013
    Publication date: April 3, 2014
    Inventors: Eline Marleen VAN DER BEEK, Gelske SPEELMANS, Antonie VAN BAALEN, Annemarie OOSTING, Günther BOEHM
  • Publication number: 20140088043
    Abstract: The present invention relates to compositions comprising omega-3 fatty acid derivatives, and in particular to compositions comprising omega-3 phospholipids in combination with other omega-3 derivatives.
    Type: Application
    Filed: September 24, 2013
    Publication date: March 27, 2014
    Applicant: AKER BIOASSIST AS
    Inventors: Nils Hoem, Lena Burri, Kjetil Berge
  • Publication number: 20140072631
    Abstract: The present invention provides combination therapy methods of treating a proliferative disease (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may include the administration of an effective amount of at least one other agent that inhibits a pro survival and/or inflammatory signal.
    Type: Application
    Filed: February 28, 2013
    Publication date: March 13, 2014
    Applicant: ABRAXIS BIOSCIENCE, LLC
    Inventor: Abraxis BioScience, LLC
  • Patent number: 8669241
    Abstract: The ophthalmic composition of the invention comprises (A) lecithin and (B) at least one refrigerant selected from the group consisting of camphor, borneol, eucalyptus oil, and bergamot oil. In the ophthalmic composition, the odor of lecithin is efficiently masked by the refrigerant. The odor of lecithin after aging is also masked by the refrigerant. Since the refrigerant is volatile, the concentration thereof in a composition tends to gradually decrease. It is surprising that the odor of lecithin after aging can nevertheless be masked.
    Type: Grant
    Filed: December 1, 2009
    Date of Patent: March 11, 2014
    Assignee: Rohto Pharmaceutical Co., Ltd.
    Inventors: Yasuko Matsumura, Mariyo Kato
  • Patent number: 8664201
    Abstract: Disclosed herein are formulations and methods of manufacture of compounds of formula (E): wherein X and Y independently represent leaving groups and A+ is an ammonium cation.
    Type: Grant
    Filed: July 30, 2009
    Date of Patent: March 4, 2014
    Assignee: Ziopharm Oncology, Inc.
    Inventors: Frank Walter Waligora, John C. Amedio
  • Patent number: 8637688
    Abstract: The present invention relates to pharmaceutical dosage forms for topical administration comprising a tri-substituted glycerol compound or a pharmaceutically acceptable salt thereof. The invention also relates to a corresponding method for preparing such dosage forms as well as to their use as medicaments for the treatment of cancer and immune diseases.
    Type: Grant
    Filed: November 9, 2007
    Date of Patent: January 28, 2014
    Inventors: Julia Diederichs, Wolfgang Richter, Lutz Weber
  • Publication number: 20140017506
    Abstract: The present application relates to wood preservation, for example, surfactants and phospholipids for improving wood preservation. Included are surfactants and phospholipids containing a 2-amino-N,N-dimethylacetamide. Provided are wood preservative compositions containing these surfactants or phospholipids, methods of applying such wood preservative compositions to wood, and wood products resultant from some such methods. Also provided are wood products containing the wood preservative compositions provided herein.
    Type: Application
    Filed: July 16, 2012
    Publication date: January 16, 2014
    Applicant: EMPIRE TECHNOLOGY DEVELOPMENT LLC
    Inventor: Atsushi Mizusawa
  • Patent number: 8613941
    Abstract: A synergistic antimicrobial composition comprising: (a) a hydroxymethyl-substituted phosphorus compound selected from the group consisting of tetrakis(hydroxymethyl)phosphonium salts and tris(hydroxymethyl)phosphine; and (b) tris(hydroxymethyl)nitromethane.
    Type: Grant
    Filed: September 13, 2013
    Date of Patent: December 24, 2013
    Assignee: Dow Global Technologies LLC
    Inventor: Bei Yin
  • Publication number: 20130337041
    Abstract: The invention provides a pharmaceutical composition comprising a synthetic or naturally occurring charged phospholipid, which is formulated into a dosage form for administration to a subject or which is administered as a food additive. Negatively charged phospholipid composition increase the net negative charge on intravascular lipoproteins, enhance the clearance of cholesterol and regulate the function of lipolytic enzymes, retard prothrombin formation and aid in the clearance of virus and bacterial particles. Negatively charged lipid compositions can therefore be administered to humans and animals for the treatment of hyperlipidemia and blood coagulation disorders and to reduce the levels of virus, bacteria, and endotoxins in the blood stream. Positively charged lipid compositions can be administered to delay lipoprotein clearance from the plasma compartment and give longer duration of activity for drugs which are associated with lipoproteins.
    Type: Application
    Filed: February 25, 2013
    Publication date: December 19, 2013
    Applicants: Ottawa Heart Institute Research Corporation, Cerenis Therapeutics, S.A.
    Inventors: Cerenis Therapeutics, S.A., Ottawa Heart Institute Research Corporation
  • Publication number: 20130338058
    Abstract: In one embodiment, the invention provides a method of suppressing, inhibiting, preventing, or treating conjunctivitis in a subject, comprising the step of administering an effective amount of a lipid or phospholipid moiety bound via an ester or amide bond to a physiologically acceptable monomer, dimer, oligomer, or polymer, and/or a pharmaceutically acceptable salt or a pharmaceutical product thereof to a subject with conjunctivitis.
    Type: Application
    Filed: January 9, 2013
    Publication date: December 19, 2013
    Applicant: YISSUM RESEARCH DEVELOPMENT COMPANY
    Inventor: YISSUM RESEARCH DEVELOPMENT COMPANY